Zota Health Care Ltd. · NSE:ZOTA
Zota Health Care — Q2 FY27 Earnings Presentation
48 slides from Zota Health Care's earnings presentation, Oct 28, 2026
Slide 1: NSE Regulation 30 cover letter
October 28, 2026 To, The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Dear Sir/ Madam, Trading Symbol: ZOTA Sub: Investor Presentation Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirem
Slide 2: Investor Presentation Q2FY27
Zota Health Care Limited INVESTOR PRESENTATION Q2FY27
Slide 3: Safe Harbour
Safe Harbour This presentation has been prepared by the Zota Health Care Limited (the “Company”) only for information purpose to the stakeholders and does not contain any offer or invitation to subscribe the securities of the Company. No offering of securities shall be made except by means of offer
Slide 4: Agenda
AGENDA Company Overview Business Overview Davaindia Domestic Operations Export Operations Financial Overview 3
Slide 5: Company Overview
neanearenta, | NSP GENERIC PHARMACY. Company Overview
Slide 6: Zota Healthcare At a Glance
Zota Healthcare At a Glance Financial Highlights (H1FY26 - Consolidated) Revenue from Operations Zota Health Care Ltd., a Headquartered in Surat and Davaindia, launched in 2017, The strategic business model publicly listed company on employing dedicated is a retail generic pharmacy allows Davaindia
Slide 7: Our Journey
Our Journey Strengthening Core And Pioneering Davaindia Setting Up Formulations 2017 2018 Export Business Introduced Davaindia, a private sector Achieved ₹10+ Cr in Export Sales; & 75+ generic pharmacy, via three pilot outlets Davaindia stores Foundational Steps In Domestic Marketing 2010 2011 2019
Slide 8: Management Profile
Management Profile Ketankumar Zota Moxesh Zota Sujit Paul Chairman And Managing Director Group Chief Executive Non-executive Director Officer Total Experience: 38+ Total Experience: 10+ Total Experience: 23+ • Holds a D-Pharmacy degree • Holds a Bachelor’s degree in pharmacy & • Featured on Times No
Slide 9: Company Structure
Company Structure Step down subsidiary Supplying products at ALP* Davaindia Zota Health Care Limited (Listed entity) (Davaindia Health Mart Limited) Procurement in listed entity FOFO Domestic Export COCO (Sales to FOFO# stores) (COCO# stores) FOFO Sales through COCO Sales through Zota Health Care Da
Slide 10: Business Overview
neanearenta, | NSP GENERIC PHARMACY. Business Overview
Slide 11: Business Verticals
Business Verticals DAVAINDIA Revenue contribution (H1FY27) • A Retail generic pharmacy chain providing quality generic medicines. Focuses only on private-label products in: 02Store variants 30% – 90% Everyday Herbal Group • Company Owned Company Operated Savings on medicines as Exports • Medicinal |
Slide 12: Case Study – Savings on Davaindia margins
Case Study – Savings on Davaindia margins Company marketed by > Indian Pharma MNC 1 Indian Pharma MNC 2 Davaindia Same Tablet with Significant savings Molecule Rosuvastatin 10mg Rosuvastatin 10mg Rosuvastatin 10mg same molecule in margins Generic Type Branded Generic Trade Generic Generic Margins Mu
Slide 13: Davaindia
neanearenta, | NSP GENERIC PHARMACY. dj davaindia’ GENERIC PHARMACY
Slide 14: Davaindia - Retail Pharmacy Chain data
Davaindia - Retail Pharmacy Chain data Revolutionizing the generic pharmacy industry with affordable, accessible, quality healthcare solutions through retail pharmacies’ chain. 2000+ 2,840* 1,859 981 SKUs Total no. COCO stores FOFO Stores of stores *As of 30th September 2026 • Launched in 2017, Dava
Slide 15: Davaindia - Operating Model
Davaindia - Operating Model Davaindia Health Mart Limited has Offers a cluster-based store 2,000+ SKUs with 70% medicinal Cloud-based software and AI- implemented a hyperlocal e-commerce model model, optimizing accessibility products and 30% OTC products, with based tools for real-time supply for on
Slide 16: Davaindia - Eliminating traditional supply chain
Davaindia - Eliminating traditional supply chain By sourcing directly from manufacturers and selling straight to consumers, traditional pharma supply chain is eliminated & the cost benefits are transferred to the consumer Average consumer price ~75% savings Doctors on Davaindia medicines as compared
Slide 17: Strengthening the Visibility
Strengthening the Visibility Mr. Mahendra Singh Dhoni & Mr. Suniel Shetty as Brand Ambassador of Davaindia 16
Slide 18: Strengthening the Visibility
Strengthening the Visibility Mr. Akshay Kumar as Brand Ambassador of Zota Health Care & UGO Generics 17
Slide 19: Davaindia – What are COCO Stores
Davaindia – What are COCO Stores COCO stores are modern walk-in stores providing a distinct contrast to traditional counter-based pharmacies enhancing customer satisfaction and loyalty. Company-Owned Company-Operated (COCO) Rapid Expansion The timeline for launching a new COCO store has been signifi
Slide 20: Davaindia - COCO Stores
Davaindia - COCO Stores States No. of Company-Operated Stores Company-Owned 1,859 West Bengal 570 Operational Uttar Pradesh 341 25 COCO stores Maharashtra 202 60 99 Delhi 70 91 Enhancing Store Kerala 97 99 Economics Haryana 91 13 Uttarakhand 70 68 341 Rajasthan 68 Gujarat 60 60 570 Punjab 60 31 Tela
Slide 21: Davaindia COCO - KPI’s (1/2)
Davaindia COCO - KPI’s (1/2) No. of Stores* Quarterly Footfall in lakhs 1855 1859 1656 48.7 1438 44.2 39.8 1207 34.3 29.6 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 *As of 30th September 2026 20
Slide 22: Davaindia COCO - KPI’s (2/2)
Davaindia COCO - KPI’s (2/2) Quarterly GMV ₹ lakhs Avg. Wallet Spend ₹ 290 ₹ 283 ₹ 13,787 270 ₹ 262 ₹ 11,569 250 ₹ 9,324 ₹ 235 ₹ 229 ₹ 231 230 ₹ 7,923 ₹ 6,780 210 190 170 150 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 *As of 30th September 2026 21
Slide 23: Store Vintage-Wise SSG Trend
Store Vintage-Wise SSG Trend Opening Period: (FY2021- FY2024) Opening Period: (FY2024 - 2025) Opening Period: (FY2025 - 2026) No. of Stores: 234 No. of Stores: 617 No. of Stores: 804 ₹ In lakhs ₹ In lakhs ₹ In lakhs Quarterly GMV Quarterly GMV Quarterly GMV ₹ 4.60 ₹ 2.59 ₹ 4.13 ₹ 2.00 ₹ 3.75 ₹ 3.74
Slide 24: SSG Performance: Period Wise Analysis
SSG Performance: Period Wise Analysis GMV in ₹lakhs/Month Q2FY26 Q1FY27 Q2FY27 8.08 7.38 7.02 5.67 5.08 4.64 3.98 3.30 3.61 2.76 2.92 3.23 2.92 2.57 2.59 2.44 2.58 2.22 2.23 2.30 1.98 2.09 1.60 1.60 1.98 1.72 April 25 to Dec 25 12+ Months 15+ Months 18+ Months 21+ Months 24+ Months 30 to 39 Months 3
Slide 25: Davaindia – What are FOFO Stores
Davaindia – What are FOFO Stores Franchisee-Owned Franchisee-Operated Asset-light franchise model (FOFO) FOFO stores employ an asset-light franchise model, contributing to the scalability and accessibility of our product offerings. Smaller Store size FOFO stores are compact and over-the-counter form
Slide 26: Davaindia - FOFO Stores
Davaindia - FOFO Stores States No. of Stores Uttar Pradesh 202 West Bengal 200 Odisha 124 18 Madhya Pradesh 78 Gujarat 60 2 Rajasthan 42 7 14 Maharashtra 40 37 3 1 30 Haryana 37 Bihar 31 42 12 981 202 Delhi 30 31 Tripura 23 1 23 Kerala 22 60 78 9 200 Operational FOFO stores Jammu & Kashmir 18 Uttara
Slide 27: Davaindia FOFO - KPI’s (1/2)
Davaindia FOFO - KPI’s (1/2) No. of Stores Quarterly Footfall 981 970 17.5 15.8 15.3 923 13.9 14.2 893 848 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2 FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 *As of 30th September 2026 26
Slide 28: Davaindia FOFO - KPI’s (2/2)
Davaindia FOFO - KPI’s (1/2) Quarterly GMV ₹ lakhs Avg. Wallet Spend 320 ₹ 5,004 ₹ 309 ₹ 4,833 310 ₹ 306 ₹ 4,711 ₹ 299 ₹ 4,249 300 ₹ 3,923 290 ₹ 286 ₹ 282 280 270 260 250 240 Q2 FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2 FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 *As of 30th September 2026 27
Slide 29: OTC (Over-the-counter) products
OTC (Over-the-counter) products Strategic Acquisition as a Acquired 87.78% stake in the Everyday Herbal Group*, move towards backward licensed by the Khadi and Village Industrial Commission, a integration strategic move towards backward integration. OTC products make up ~30% of the stock keeping uni
Slide 30: OTC (Over-the-counter) products
OTC (Over-the-counter) products 29
Slide 31: Davaindia is Revolutionizing the Indian Healthcare Scenario
Davaindia is Revolutionizing the Indian Healthcare Scenario ₹35,193 lacs ~65 % Gross Merchandise Value Davaindia Gross Margin in COCO format in H1FY26 2,840 30-90 % Savings to consumers on Fast growing FOFO & Generic medicines COCO store network* *As of 30th September 2026 25-30 % Mature COCO Stores
Slide 32: State-Wise Presence of Davaindia Across India
State-Wise Presence of Davaindia Across India (COCO & FOFO Models) States FOFO COCO Total West Bengal 200 570 770 Uttar Pradesh 202 341 543 Maharashtra 40 202 242 Odisha 124 6 130 Delhi 30 99 129 Haryana 37 91 128 Gujarat 60 60 120 Kerala 22 97 119 Rajasthan 42 68 110 Madhya Pradesh 78 31 109 Uttara
Slide 33: Davaindia Competitive Edge
Davaindia Competitive Edge The USP of Davaindia: Affordable, Trustworthy, and Innovative Pharmacy Solutions BENEFITS TO THE CUSTOMERS BENEFITS TO THE FRANCHISEES Medicines priced at low MRP thereby ensuring affordability for the masses Store operations and the supply chain efficiently managed by clo
Slide 34: Healthy Repeats
Healthy Repeats Total Average (in %) With a strong base of 80% repeat customers, Davaindia demonstrates a high level of customer satisfaction 80% and loyalty. Repeat Customers 12% New Customers 08% Lost Customers 33 33
Slide 35: Higher Chronic category share
Higher Chronic category share CATEGORY MIX FY25 CATEGORY MIX FY26 57% 60% 27% 27% 16% 13% Chronic OTC Other Chronic OTC Other Higher chronic share: A significant ~60% of our revenue comes from chronic disease category, signalling high realization and retention rates, reflecting our crucial role in s
Slide 36: Supply Chain Management
Supply Chain Management • The Company has outsourced supply chain management to a third-party warehousing & logistics partner. • A state-of-art central warehousing & processing center has been built in Surat, in Phase 1. • Eventually the Company will replicate such infrastructure across different zo
Slide 37: Domestic Operations
Domestic Operations 36
Slide 38: Domestic Operations
Domestic Operations Marketing Value Chain: Domestic marketing has been the oldest business vertical for the FDF Manufacturers Company and has remained its mainstay in the past. Until 2017, WHO-GMP certified this vertical contributed most of the Company’s revenues. This manufacturing partners busines
Slide 39: Export Operations
Export Operations 38
Slide 40: Export Operations
Export Operations Dossiers Registered In Global Markets Our Exports business vertical, which started in 2010, serves 1. Benin 15. Sri Lanka clients in over 30 countries, mainly in the CIS, Latin America, 2. Bolivia 16. Swaziland Africa, and Asia. At its plant in Sachin, SEZ, the Company 3. Cambodia
Slide 41: Financial Overview
neanearenta, | NSP GENERIC PHARMACY. Financial Overview
Slide 42: Management Commentary
Management Commentary “We are pleased with our performance during Q2FY27, as we continued to strengthen the underlying fundamentals of the business. Revenue from Operations grew by 54.58% YoY, supported by a 76.25% YoY increase in Davaindia Sales and 78.99% YoY growth in Everyday Herbal Group. Impor
Slide 43: Quarterly Revenue Segmentation
Quarterly Revenue Segmentation Business Verticals – Consolidated Revenue bifurcation Davaindia ₹ lakhs Domestic Operations ₹ lakhs Export Operations ₹ lakhs Everyday Herbal ₹ lakhs 16,847 807 14,342 2,459 649 1,095 1,791 1,791 9,559 451 574 470 Q2 FY26 Q1 FY27 Q2 FY27 Q2 FY26 Q1 FY27 Q2 FY27 Q2 FY26
Slide 44: Annually Financial Snapshot
Annually Financial Snapshot Davaindia ₹ lakhs Domestic Operations ₹ lakhs Export Operations ₹ lakhs 41,741 6,794 3,471 3,190 3,014 6,342 2,467 5,983 2,004 5,950 18,621 5,689 10,356 5,578 4,122 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Davaindia has driven revenue gro
Slide 45: Business Vertical Performance (Consolidated)
Business Vertical Performance (Consolidated) ₹ in lakhs (Consolidated) Q2 FY27 Elimination Particulars Business Vertical of Common Consolidated Transactions Davaindia Domestic Exports Everyday Others Revenue from Operation 16846.81 2459.13 470.09 806.79 21.81 -671.49 19933.14 Cost of Goods Sold 5866
Slide 46: Profit & Loss Statement (Consolidated)
Profit & Loss Statement (Consolidated) Particulars (₹ in Lakhs) Q2FY27 Q1FY27 Q2FY26 H1FY27 H1FY26 Export Sales (SEZ) 470.09 573.51 1,094.98 1,043.60 1,759.06 Davaindia Sales 16,846.81 14,342.33 9,558.59 31,189.14 17,121.49 Domestic Sales 2,459.13 1,790.67 1,790.50 4,249.80 3,297.37 Everyday Herbal
Slide 47: Balance sheet (Consolidated)
Balance sheet (Consolidated) ₹ in lakhs (Consolidated) As at As at As at As at Assets Equity and Liabilities 30th September 2026 31st March 2026 30th September 2026 31st March 2026 Non-Current Assets (i) Equity Share capital 3,463.26 3,463.26 Property, plant and equipment 14,053.61 14,041.17 (ii) Ot
Slide 48: Thank You
Borcelle Clinic Health for all THANK YOU "ZOTA HOUSE", Bhagwan Siddesh Chawan - Ayyappa Complex, Navsari [email protected] State Highway, opp. GIDC Main Road, Surat, Gujarat 394210 Ajit Mishra - [email protected] [email protected] www.zotahealthcare.com 47